TF Capital logo

TF Capital

Asia, Shandong, China, Pudong

Description

TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.

Investor Profile

TF Capital has made 15 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (60%)
  • Series B (33%)
  • Series C (7%)

Country Focus

  • China (53%)
  • United States (47%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Biopharma
  • Therapeutics
  • Life Science
  • Oncology
  • Neuroscience
  • Product Research
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does TF Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 3
INCE Capital
Asia, Shandong, China, Pudong
Co-Investments: 3
Frontline BioVentures
Asia, Shanghai, China, Shanghai
Co-Investments: 2
WuXi Healthcare Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 3
Ally Bridge Group
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 2
SAIL Capital Partners LLC
North America, California, United States, Corona Del Mar
Co-Investments: 2
HongShan
Asia, Beijing, China, Beijing
Co-Investments: 5
Qiming Venture Partners
Asia, Shanghai, China, Shanghai
Co-Investments: 8
Lilly Asia Ventures
Asia, Shanghai, China, Shanghai
Co-Investments: 3
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 3

What are some of recent deals done by TF Capital?

Avenzo Therapeutics

San Diego, California, United States

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

BiotechnologyHealth CareMedicalOncologyTherapeutics
Series ANov 18, 2024
Avenzo Therapeutics

San Diego, California, United States

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

BiotechnologyHealth CareMedicalOncologyTherapeutics
Series AMar 26, 2024
Amount Raised: $150,000,000
Allorion Therapeutics

Natick, Massachusetts, United States

Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.

MedicalPharmaceuticalTherapeutics
Series BMar 9, 2023
Amount Raised: $50,000,000
Allorion Therapeutics

Natick, Massachusetts, United States

Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.

MedicalPharmaceuticalTherapeutics
Series ANov 24, 2021
Amount Raised: $40,000,000
Structure Therapeutics

South San Francisco, California, United States

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

BiotechnologyHealth CareMedicalPharmaceuticalProduct Research
Series BOct 20, 2021
Amount Raised: $100,000,000
Cellular Biomedicine Group

Palo Alto, California, United States

CBMG is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies.

BiotechnologyMedical DeviceTherapeutics
Series ASep 28, 2021
Amount Raised: $120,000,000
SciNeuro

Rockville, Maryland, United States

SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.

BiopharmaBiotechnologyNeuroscience
Series ADec 8, 2020
Amount Raised: $100,000,000
Angitia Biopharmaceuticals

Guangzhou, Guangdong, China

Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.

BiopharmaBiotechnologyHealth CareMedical
Series ASep 4, 2020
Antengene Corporation

Shanghai, Shanghai, China

Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.

BiopharmaBiotechnologyLife SciencePharmaceutical
Series BJan 2, 2019
Amount Raised: $120,000,000
Antengene Corporation

Shanghai, Shanghai, China

Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.

BiopharmaBiotechnologyLife SciencePharmaceutical
Series AAug 16, 2017
Amount Raised: $21,000,000